WINTON GROUP Ltd Buys 202,384 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

WINTON GROUP Ltd increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 380.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 255,600 shares of the biotechnology company’s stock after acquiring an additional 202,384 shares during the period. WINTON GROUP Ltd’s holdings in BioCryst Pharmaceuticals were worth $2,556,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BCRX. Nykredit A S bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $27,000. Larson Financial Group LLC raised its holdings in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. IFP Advisors Inc lifted its position in BioCryst Pharmaceuticals by 2,515.3% during the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 3,119 shares during the period. Allworth Financial LP bought a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $52,000. Finally, Focus Partners Wealth bought a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth about $77,000. 85.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Royal Bank Of Canada lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $13.00 to $11.00 in a research note on Thursday. Cantor Fitzgerald upped their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.40.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $8.12 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The business’s fifty day moving average is $9.65 and its 200 day moving average is $9.23. The stock has a market capitalization of $2.07 billion, a PE ratio of -5.41 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 EPS. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.